Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.^1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.⁵

“We are proud to celebrate the one million Vivity eyes empowering cataract patients to see the world with high quality vision from distance to functional near—day and night,” said Sean Clark, President, Global Surgical Franchise at Alcon. “This milestone embodies our commitment to addressing the diverse vision needs of today's patients, who desire less dependence on glasses post-surgery and low visual disturbances, with a game-changing presbyopia-correcting intraocular lens (PCIOL) option that expands the patient candidacy pool.”

Vivity uses Alcon’s patented non-diffractive Wavefront-Shaping X-WAVE technology, an advanced optical principle that simultaneously stretches and shifts light without splitting it—balancing quality of vision and maximizing range of vision.^2,3 The optic delivers excellent distance and intermediate vision, as well as functional near vision.² The unique mechanism of action is not refractive, does not introduce spherical aberrations and has ultimately expanded PCIOL access to even more patients. Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.

Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe. The Vivity Registry Study⁴⁺ includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy, as well as post-refractive eyes. The Registry data demonstrates high patient satisfaction among several patient cohorts, as the vast majority of patients (92%) report they are satisfied with their sight.^∞ Additionally, more than 91% of patients report no haloes, glares, or starbursts.^†

Vivity is available in more than 80 countries, including Australia, Brazil, Canada, China, France, Germany, Japan, India, Italy, Russia, South Korea, Spain, U.K. and U.S. Alcon offers a family of leading IOLs designed to meet the unique vision needs of patients, including Vivity and PanOptix—the most implanted PCIOLs worldwide—as well as monofocal and toric options. PanOptix surpassed one million implants in early 2022, and is the most implanted trifocal worldwide.^5,6 For more information, please visit www.ClareonIOL.com.